Editas Q4 2021 Earnings Report
Key Takeaways
Editas Medicine reported a net loss of $41.4 million for the fourth quarter of 2021, with collaboration and other research and development revenues increasing to $12.5 million. The company's cash, cash equivalents, and marketable securities totaled $619.9 million as of December 31, 2021, expected to fund operations through 2023.
EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022
EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and first TDT patient in 2022
EDIT-103 for RHO-adRP and EDIT-202 for solid tumors advancing towards IND-enabling studies
First ever in vivo ocular gene editing data demonstrated evidence of gene editing and potential clinical benefit; clinical update expected in 2H 2022
Editas
Editas
Forward Guidance
Editas Medicine anticipates several milestones in 2022, including clinical data updates for EDIT-101 and EDIT-301, the start of patient dosing in the beta thalassemia trial, and the beginning of IND-enabling studies for EDIT-202.
Positive Outlook
- Completing dosing of the pediatric mid-dose cohort in the first half of 2022
- Initiating dosing of the pediatric high-dose cohort in the BRILLIANCE trial in 2022
- Establishing registrational trial criteria by year-end 2022
- Dosing the first patient in the RUBY trial in the first half of 2022
- Dosing the first TDT patient with EDIT-301 in 2022
Challenges Ahead
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials
- Availability and timing of results from pre-clinical studies and clinical trials
- Whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials
- Expectations for regulatory approvals to conduct trials or to market products
- Availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements